Document:

exv10w4

Exhibit 10.4

FIRST AMENDMENT TO

EMPLOYMENT AGREEMENT

     Medicis Pharmaceutical Corporation (the “Company”) and Richard D. Peterson (the
“Executive”) entered into an Employment Agreement (the “Agreement’) effective December
22, 2008. The Company and Executive wish to amend the Agreement to modify the Executive’s
salary to reflect the Executive’s additional responsibilities and to clarify the
circumstances in which a change in the Executive’s authority, duties or
responsibilities will be deemed to give rise to “Good Reason” for the Executive to terminate
the Agreement. The Company and Executive each acknowledge that the modification of the
Executive’s salary and the noted clarification is valuable to it or him and provides adequate
consideration for the execution of this First Amendment.

     1. This First Amendment is effective as of June 30, 2010.

     2. Section 3.1 of the Agreement is hereby amended to provide that
Executive’s salary, effective as of the effective date of this First Amendment,
shall be increased to an annual rate of $555,000 per year.

     3. Section 5.6(b) of the Agreement is hereby amended and restated in its entirety to
read
follows:

     (b) a material diminution in Executive’s
authority, duties or responsibilities as set forth in
Section 2.1, provided, however, that for
purposes of this clause (b) a change in Executive’s
authority, title, duties, or responsibilities shall not
be deemed to materially reduce Executive’s authority,
duties, or responsibilities if all of the following
conditions are satisfied: (i) at the time the change is
implemented Jonah Shacknai is serving as Company’s
Chief Executive Officer; (ii) Mr. Shacknai initiated or
approved the change; (iii) Executive continues to
report to either the supervisor to whom Executive
reported immediately prior to such change or a
supervisor at the same or higher level of
responsibility within Company’s organizational
structure; and (iv) there is no material diminution in
Executive’s Base Compensation or in Executive’s
opportunities for incentive or equity compensation.

     4. This First Amendment amends only the provisions of the Agreement as set forth

 

herein, and those provisions not expressly amended by this First Amendment
shall continue in full force and effect. Notwithstanding the foregoing, this First
Amendment shall supersede the provisions of the Agreement to the extent those
provisions are inconsistent with the provisions and the intent of this First
Amendment.

     IN WITNESS WHEREOF, Executive has executed this First Amendment, and Company
has
caused this First Amendment to be executed by its duly authorized
representative, on this 15th day of
June, 2010.

	 	 	 	 	 
	 	MEDICIS PHARMACEUTICAL CORPORATION

 	 
	 	By  	/s/ Jason D. Hanson
 	 
	 	 	Its Jason D. Hanson 	 
	 	 	Executive Vice President, General
Counsel & Corporate Secretary 	 
	 
	 	“EXECUTIVE”

 	 
	 	/s/ Richard D. Peterson
 	 
	 	 	 
	 	 	 
	 

2exv10w5

Exhibit 10.5

FIRST AMENDMENT TO

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

     Medicis Pharmaceutical Corporation (the “Company”) and Mark A. Prygocki (the
“Executive”) entered into an Amended and Restated Employment Agreement (the
“Agreement”) effective as of December 22, 2008. The Company and Executive wish to
amend the Agreement to modify the description of the Executive’s position and duties
and to clarify the circumstances in which a change in the Executive’s
authority, duties or responsibilities will be deemed to give rise to “Good
Reason” for the Executive to terminate the Agreement. The Company and Executive each
acknowledge that the modification of the Executive’s position and duties and the
noted clarification are valuable to it or him and provide adequate
consideration for the execution of this First Amendment.

     1. This First Amendment is effective as of June 30, 2010.

     2. Section 2.1 of the Agreement is hereby amended and restated in its entirety to
read as
follows:

     2.1 Position and Duties. Executive shall serve
as the President of the Company and shall have such
authority, duties and responsibilities as ordinarily
assigned to an employee holding the position of President
with a publicly traded company (or following a Change in
Control, the ultimate parent entity of Company) and
provided to Executive in writing. Executive shall also have
such additional authority, duties and
responsibilities as may be assigned to him by the Company
from time to time with his consent.

     3. Section 3.1 of the Agreement is hereby amended to provide that
Executive’s salary, effective as of the effective date of this First Amendment, shall
be increased to an annual rate of $670,000 per year.

     4. Section 5.6(b) of the Agreement is hereby amended and restated in its entirety to
read
follows:

     (b) a material diminution in Executive’s
authority, duties or responsibilities as set forth in
Section 2.1, provided, however, that for purposes of this
clause (b) a change in Executive’s authority, title,
duties, or responsibilities shall not be deemed to
materially reduce Executive’s authority, duties, or
responsibilities if all of the following conditions are
satisfied: (i) at the time the change is implemented Jonah
Shacknai is serving as Company’s Chief Executive Officer;
(ii) Mr. Shacknai initiated or approved the change; (iii)
Executive

 

continues to report to either the supervisor to whom
Executive reported immediately prior to such change or a
supervisor at the same or higher level of responsibility
within Company’s organizational structure; and (iv) there
is no material diminution in Executive’s Base
Compensation or in Executive’s opportunities for
incentive or equity compensation.

     5. Section 5.6(f) of the Agreement is hereby amended and restated in its
entirety to read
as follows:

     (f) any other action or inaction that constitutes a
material breach by the Company of the Agreement (including
without limitation the breach by the Company of its
obligation under Section 2.1 to maintain Executive’s
duties as those consistent with the duties of a
President of a publicly traded company or following a
Change in Control, as President of the ultimate
parent entity of the Company).

     6. This First Amendment amends only the provisions of the Agreement as set
forth
herein, and those provisions not expressly amended by this First Amendment shall
continue in full force and effect. Notwithstanding the foregoing, this First
Amendment shall supersede the
provisions of the Agreement to the extent those provisions are inconsistent with the
provisions and
the intent of this First Amendment.

     IN WITNESS WHEREOF, Executive has executed this First Amendment, and Company
has
caused this First Amendment to be executed by its duly authorized
representative, on this 15th day of
June, 2010.

	 	 	 	 	 
	 	MEDICIS PHARMACEUTICAL CORPORATION

 	 
	 	By  	/s/ Jason D. Hanson
 	 
	 	 	Its Jason D. Hanson 	 
	 	 	Executive Vice President, General
Counsel & Corporate Secretary 	 
	 
	 	“EXECUTIVE”

 	 
	 	/s/ Mark A. Prygocki
 	 
	 	 	 
	 	 	 
	 

2exv4w1

Exhibit 4.1

FORM OF AMENDMENT NO. 1 TO

SECOND AMENDED AND RESTATED WARRANT AGREEMENT

     This Amendment (this “Amendment”) is made as of [               ], 2010 by and among Liberty
Acquisition Holdings Corp., a Delaware corporation (the “Company”), Liberty Acquisition
Holdings Virginia, Inc., a Virginia corporation (“Liberty Virginia”), Continental Stock
Transfer & Trust Company, a New York corporation (the “Warrant Agent”), and Promotora de
Informaciones, S.A., a sociedad anónima organized under the laws of Spain (“PRISA”).

     WHEREAS, the Company and the Warrant Agent are parties to that certain Second Amended and
Restated Warrant Agreement, dated as of December 6, 2007 and filed with the United States
Securities and Exchange Commission on December 12, 2007 (the “Existing Warrant Agreement”),
pursuant to which the Company has issued Warrants to purchase 76,687,500 shares of Common Stock
(collectively, the “Warrants”);

     WHEREAS, the terms of the Warrants are governed by the Existing Warrant Agreement and
capitalized terms used herein, but not otherwise defined, shall have the meanings given to such
terms in the Existing Warrant Agreement;

     WHEREAS, on August 4, 2010, the Company, Liberty Virginia and PRISA entered into an Amended
and Restated Business Combination Agreement (as amended from time to time, the “Business
Combination Agreement”), pursuant to which, upon the consummation of the transactions
contemplated by the Business Combination Agreement, the stockholders of the Company will come to
own newly issued American Depositary Receipts representing newly issued (i) Class A Ordinary Shares
of PRISA and (ii) convertible non-voting shares (acción sin voto convertible) of PRISA;

     WHEREAS, the Business Combination Agreement provides for the merger of the Company with and
into Liberty Virginia, its wholly owned subsidiary, upon consummation of which, as provided in
Section 4.4 of the Existing Warrant Agreement, the Warrants will no longer be exercisable for
shares of Common Stock but instead will be exercisable (subject to the terms and conditions of the
Existing Warrant Agreement as amended hereby) for shares of common stock, par value $0.0001 per
share, of Liberty Virginia;

     WHEREAS, the Board of Directors of the Company has determined that the consummation of the
transactions contemplated by the Business Combination Agreement will constitute a Business
Combination between the Company and PRISA;

     WHEREAS, pursuant to the Business Combination Agreement, the Company agreed to seek the
approval of this Amendment by the Registered Holders of a majority of the outstanding Warrants (the
“Warrant Proposal”) such that, in connection with the transactions contemplated by the
Business Combination Agreement, PRISA will be required to purchase, and the holders of Warrants
will be required to exchange, all of the outstanding Warrants for the Consideration (as defined
below) and on such other terms and subject to such conditions as are set forth herein;

     WHEREAS, Section 9.8 of the Existing Warrant Agreement provides that the Company and the
Warrant Agent may amend the Existing Warrant Agreement with the written consent of the Registered
Holders of a majority of the outstanding Warrants;

 

 

     WHEREAS, the Registered Holders of a majority of the outstanding Warrants have approved the
Warrant Proposal; and

     WHEREAS, the representative of the underwriters has waived any and all rights to consent to
any modification or amendment of the Existing Warrant Agreement contemplated by Section 9.8 of the
Existing Warrant Agreement.

     NOW, THEREFORE, in consideration of the mutual agreements contained herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending
to be legally bound hereby, the parties hereto agree to amend the Existing Warrant Agreement as set
forth herein.

     1. Amendment of Existing Warrant Agreement.

     1.1 Mandatory Exchange of Securities. Section 6 of the Existing Warrant Agreement is
hereby amended and restated in its entirety so that it now reads in full as follows:

     “6 Mandatory Exchange of Securities.

     6.1 Definitions.

     Capitalized terms used in this Section 6, but not otherwise defined in this
Agreement, shall have the meanings given to such terms in the Amended and Restated Business
Combination Agreement, dated as of July ___, 2010, by and between Promotora de Informaciones,
S.A., a sociedad anónima organized under the laws of Spain (“PRISA”), Liberty
Acquisition Holdings Corp. and Liberty Acquisition Holdings Virginia, Inc., a Virginia
corporation (“Liberty Virginia”) (the “Business Combination Agreement”) , a
copy of which is included in the PRISA prospectus dated [___], 2010 and previously
delivered to Registered Holders in connection with soliciting consents for Amendment No. 1
to this Agreement.

     6.2 Exchange.

     6.2.1 Notwithstanding anything contained in this Agreement to the contrary, at the
Exchange Effective Time, and subject to the Share Exchange being consummated, except as
provided in Section 6.3 herein or as such consideration may be changed as occasioned
by the last paragraph of Section 3.5(a) of the Business Combination Agreement, each Warrant
issued and outstanding immediately prior to the Exchange Effective Time shall, automatically
and without any action by the Registered Holder thereof, be exchanged by PRISA and
transferred by such Registered Holder to PRISA (the “Warrant Exchange”), in
consideration for:

     (i) a payment by Liberty Virginia in cash in the amount of US$0.90 (the
“Cash Consideration”) to be delivered by or at the direction of Liberty
Virginia; and

     (ii) the exchange by PRISA of 0.450 newly issued PRISA Class A Ordinary Shares
(the “Ordinary Share Consideration,” and together with the Cash
Consideration, the “Consideration”) to be delivered by PRISA to the
Depositary as provided for herein.

2

 

     6.2.2 Notwithstanding anything contained in this Agreement to the contrary, upon
consummation of the Share Exchange, and without any action by the Registered Holder thereof,
each Registered Holder of Warrants (other than Prisa) shall cease to have any rights with
respect to the Warrants other than the right to receive the Consideration.

     6.3 Delivery of Consideration.

     6.3.1 Each PRISA Share issued as part of the Consideration shall be registered in the
name of the Depositary by Iberclear and then delivered in the form of PRISA ADSs evidenced
by ADRs, with each PRISA ADS-A representing [___] PRISA Class A Ordinary Shares. Each PRISA
ADS shall be issued in accordance with the Deposit Agreement.

     6.3.2 The aggregate Cash Consideration payable to each former Registered Holder shall
be rounded down to the nearest whole cent after multiplying the aggregate number of
outstanding Warrants held by such former Registered Holder by the Cash Consideration.

     6.3.3 If, between the date of this Agreement and the Exchange Effective Time, PRISA,
Liberty or Liberty Virginia undergoes a change in capitalization affecting the Warrants, an
appropriate and proportionate adjustment shall be made to the Ordinary Share Consideration
in order to preserve the economic benefits of the Warrant Exchange to the parties.

     6.3.4 In so far as the provisions of Article IV of the Business Combination Agreement
relate to the obligations and rights of the parties to this Agreement regarding the Warrant
Exchange, such provisions are hereby incorporated herein by reference; provided,
however, that nothing in this Section 6.3.4 or this Agreement, whether
expressed or implied, is intended to confer upon any Person, including any beneficial owner
or Registered Holder of Warrants, any rights or remedies under or by reason of the Business
Combination Agreement enforceable against the parties thereto or their successors or
assigns.

     6.3.5 Notwithstanding anything herein to the contrary, the Company shall not be
required to provide any prior notice of the Warrant Exchange to any Registered Holder.

     6.4 Each of the parties hereto acknowledges and agrees that the obligations under this
Section 6 to deliver the Ordinary Share Consideration shall be satisfied by PRISA.

     6.5 Each of the parties hereto acknowledges and agrees that the obligations under this
Section 6 to deliver the Cash Consideration shall be satisfied by or at the
direction of Liberty Virginia.”

3

 

     1.2 Appointment of Warrant Agent. Existing Warrant Agreement is hereby amended to add
a new Section 1.2, which shall read in full as follows:

“1.2 Appointment of Warrant Agent at Exchange Time. Notwithstanding anything
contained in this Agreement to contrary (including that the Warrant Agent be a New York
Corporation), at the Exchange Effective Time, PRISA shall act as agent for the Company, its
successors and assigns for the Warrants, and PRISA agrees to perform in accordance with the
terms and conditions set forth in this Agreement. At such time as PRISA is appointed,
Continental Stock Transfer & Trust Company shall have no further rights or obligations under
the Agreement, and the term “Warrant Agent,” as used in this Agreement, shall refer
exclusively to PRISA.”

     2. Miscellaneous Provisions.

     2.1 PRISA Obligation. Each of the parties hereto acknowledges and agrees that the
obligations under Section 6.2 of the Existing Warrant Agreement (as amended by this Amendment) to
deliver the Ordinary Share Consideration and Convertible Non-Voting Share Consideration shall be
satisfied by PRISA

     2.2 Liberty Virginia Obligation. Each of the parties hereto acknowledges and agrees
that the obligations under Section 6.2 of the Existing Warrant Agreement (as amended by this
Amendment) to deliver the Cash Consideration shall be satisfied by or at the direction of Liberty
Virginia.

     2.3 Effectiveness of Warrant. Each of the parties hereto acknowledges and agrees that the effectiveness of this Amendment
shall be expressly subject to the occurrence of the Share Exchange (as defined in the Business
Combination Agreement) and shall automatically be terminated and shall be null and void if the
Business Combination Agreement shall be terminated.

     2.4 Successors. All the covenants and provisions of this Amendment by or for the
benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their permitted
respective successors and assigns.

     2.5 Severability. This Amendment shall be deemed severable, and the invalidity or
unenforceability of any term or provision hereof shall not affect the validity or enforceability of
this Amendment or of any other term or provision hereof. Furthermore, in lieu of any such invalid
or unenforceable term or provision, the parties hereto intend that there shall be added as a part
of this Amendment a provision as similar in terms to such invalid or unenforceable provision as may
be possible and be valid and enforceable.

     2.6 Applicable Law. The validity, interpretation and performance of this Amendment
shall be governed in all respects by the laws of the State of New York, without giving effect to
conflict of laws. The parties hereby agree that any action, proceeding or claim against it arising
out of or relating in any way to this Amendment shall be brought and enforced in the courts of the
State of New York or the United States District Court for the Southern District of New York, and
irrevocably submits to such jurisdiction, which jurisdiction shall be
exclusive. Each of the parties hereby waives any objection to such exclusive jurisdiction and
that such courts represent an inconvenient forum.

4

 

     2.7 Counterparts. This Amendment may be executed in any number of counterparts, and
by facsimile or portable document format (pdf) transmission, and each of such counterparts shall
for all purposes be deemed to be an original and all such counterparts shall together constitute
but one and the same instrument.

     2.8 Effect of Headings. The Section headings herein are for convenience only and are
not part of this Amendment and shall not affect the interpretation thereof.

     2.9 Entire Agreement. The Existing Warrant Agreement, as modified by this Amendment,
constitutes the entire understanding of the parties and supersedes all prior agreements,
understandings, arrangements, promises and commitments, whether written or oral, express or
implied, relating to the subject matter hereof, and all such prior agreements, understandings,
arrangements, promises and commitments are hereby canceled and terminated.

[Signatures Appear on Following Page]

5

 

     IN WITNESS WHEREOF, each of the parties has caused this Amendment to be duly executed as of
the date first above written.

	 	 	 	 	 
	 	LIBERTY ACQUISITION HOLDINGS CORP.

 	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 
	 	LIBERTY ACQUISITION HOLDINGS

VIRGINIA, INC.

 	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 
	 	CONTINENTAL STOCK TRANSFER &

TRUST COMPANY

 	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

	 	 	 	 	 
	 	PROMOTORA DE INFORMACIONES, S.A.

 	 
	 	By:  	
 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

[Signature Page to Warrant Agreement Amendment]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]